Antigenics Inc.
Antigenics Inc. is a biotechnology company founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company focuses on cancer vaccines, immunotherapeutics, adjuvants and infectious disease treatments. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Antigenics acquired Aquila Biopharmaceuticals and in 2001 also acquired Aronex Pharmaceuticals. Antigenics has over 80 U.S. patents, many of which relate to its proprietary heat shock protein technology upon which its experimental cancer vaccine Oncophage is built.
[edit] Articles
Wall Street Journal article on company and FDA
A roundup of news announcing the filing in Russia and the quarterly update.
[1]
|
